PPI

ITS Logistics Distribution + Fulfillment Q4 Index: Economy Closes 2023 with a ‘Slowcession’

Retrieved on: 
torsdag, december 7, 2023
Asset, Movement, GDP, PPI, Producer, Logistics, Growth, Transport

RENO, Nev., Dec. 07, 2023 (GLOBE NEWSWIRE) -- ITS Logistics today released the Q4 ITS Logistics US Distribution + Fulfillment Index, Powered by Cresa .

Key Points: 
  • RENO, Nev., Dec. 07, 2023 (GLOBE NEWSWIRE) -- ITS Logistics today released the Q4 ITS Logistics US Distribution + Fulfillment Index, Powered by Cresa .
  • This quarter, the Index reveals that the economy is currently experiencing a “slowcession” as the freight industry pushes through what feels like a recession.
  • ITS Logistics offers a full suite of network transportation solutions across North America and omnichannel distribution and fulfillment services to 95% of the U.S. population within two days.
  • Visit here for a full, comprehensive copy of the index with expected forecasts for the US distribution and fulfillment sector of the supply chain industry.

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Retrieved on: 
onsdag, december 6, 2023
Quality of life, CYP, Kidney, Risk, Heartburn, Enzyme inhibitor, FDA, TIN, Hypertension, Achlorhydria, Magnesium, Liver, PPI, SJS, Magnesium deficiency, Chest pain, Atazanavir, Endoscopy, Impairment, SCAR, Vitamin B12, Malabsorption, Absorption, PDUFA, CDAD, Calcium, New Drug Application, Gastritis, Enzyme, Food and Drug Administration, Clostridioides, Vonoprazan, Patient, Hip, Hypokalemia, Food, Polyp, GERD, Nelfinavir, Toxicity, EGFR, Wrist, Diarrhea, Hypocalcemia, NDA, Abdominal pain, Urinary tract infection, Hypersensitivity, Stevens–Johnson syndrome, Glomus tumor, Spine, Indigestion, Drug, CGA, Lactation, Pharmaceutical industry

The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

Key Points: 
  • The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
  • “Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life.
  • Symptoms impact overall quality of life and can include episodic heartburn, especially at night, regurgitation, problems swallowing, and chest pain.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on: 
tisdag, november 28, 2023
HIV-1, Risk, Heartburn, MOA, Enzyme inhibitor, Potassium, FDA, Magnesium, Nausea, PPI, Inflammation, Prescription, Esophagus, Bone fracture, Skin, Chills, Extrapyramidal system, Fever, Vitamin, Breast milk, Infection, Diarrhea, Helicobacter pylori, Indigestion, Bleeding, Disease, Muscle weakness, Tongue, Calcium, Acid, University, Human, Pharmacy, Clostridioides, Vonoprazan, Urine, Hip, B-12, Food, Polyp, Esophagitis, GERD, Chronic pain, Blood, Dizziness, Blister, Gastroesophageal reflux disease, Tablet, Vitamin B12, Scar, Patient, Wrist, Medicine, Seizure, HIV, Stomach, Lymph, Allergy, Clostridioides difficile, Rash, Weakness, Urinary tract infection, Hypoesthesia, Week, Myalgia, Spine, Spasm, Kidney, Face, Rilpivirine, Lansoprazole, Pharmaceutical industry

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points: 
  • “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
  • “Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
  • Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
  • for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

Pender Growth Fund Provides Financial Highlights and Company Updates

Retrieved on: 
torsdag, november 23, 2023
Portfolio company, Environment, Bank statement, Fairness opinion, Acalypha, PPI, Cryptocurrency

There can be no assurance that the Company will be able to realize the value of this investment.

Key Points: 
  • There can be no assurance that the Company will be able to realize the value of this investment.
  • During the third quarter, overall market sentiment was more challenging, with equities and risk assets broadly lower over the period.
  • We believe that this environment provides compelling opportunities for long term focused investors and that the Company is well-positioned to continue to pursue its investment objectives.
  • At September 30, 2023, the Company held 100% of the Legacy Shares of PPI, formerly the Working Opportunity Fund (EVCC) Ltd. (“WOF”).

United States VOQUEZNA TRIPLE and DUAL PAKs Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
onsdag, december 20, 2023
Infectious Diseases, Pharmaceutical, Health, Amoxicillin, Infection, Research, FDA, Helicobacter pylori, SWOT, Vonoprazan, PPI, NDA, NERD, Clarithromycin, DUAL, Pharmaceutical industry

The "US VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about VOQUEZNA TRIPLE and DUAL PAKs for Helicobacter pylori (H. pylori) infection in the United States.
  • A detailed picture of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori.
  • This report provides a detailed market assessment of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States.

Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Oral Solution

Retrieved on: 
måndag, december 4, 2023
Biotechnology, FDA, Managed Care, Health, General Health, Women, Seniors, Pharmaceutical, Research, Consumer, Science, Breakfast, Heat intolerance, Absorption, Food, Hypothyroidism, Eating, Commercial Operating System, Irritability, Headache, Risk, Tremor, Arrhythmia, IBSA, Rash, Cardiovascular disease, Insurance, Patient, Diabetes, Myocardial infarction, Periodic breathing, Appetite, Atrial fibrillation, Muscle weakness, Enzyme inhibitor, Adrenal insufficiency, Diarrhea, Menstruation, University, Water, Insomnia, PPI, Glycerol, Common, Spasm, Nervous, Hyperthyroidism, Weight loss, Pharmacy, Pharmaceutical industry, Dietary supplement, Levothyroxine

The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.
  • The first regards the use of Tirosint-SOL in the presence of proton pump inhibitor (PPI) therapy.
  • Both label changes help to differentiate Tirosint-SOL from other levothyroxine therapies.
  • Similarly, current labeling for all levothyroxine sodium therapies instructs patients to self-administer the drug once daily, on an empty stomach, one-half to one hour before breakfast.

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Retrieved on: 
torsdag, november 30, 2023
MSD, Health equity, Research, Entrepreneurship, Clinical trial, Patient, Participation, Enhanced, Cancer, Health education, PPI, Orientation, Pharmaceutical industry, Merck

BIRMINGHAM, Ala., Nov. 30, 2023 /PRNewswire/ -- Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck's oncology clinical studies.

Key Points: 
  • "We're proud to be working with Merck because being a champion for health equity through inclusive research takes strategic orientation and proactiveness.
  • Additionally, Acclinate will contribute its proprietary predictive analytics tool, e-DICT (Enhanced Diversity in Clinical Trials), that provides real-time reporting on community access and engagement activities and insights into potential participants.
  • "Community engagement is a key step toward increasing diversity in clinical trials," said Adrelia Allen, Executive Director, Clinical Trial Patient Diversity, Merck.
  • "We're excited to collaborate with Acclinate to raise awareness among the Black/African American community of available clinical trials for people with cancer.

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

Retrieved on: 
tisdag, november 28, 2023
Dai, PRISM, PPI, Lilly, Patient, License, System Technology-i Co, Ltd, Eli Lilly and Company, Drug discovery, Pharmaceutical industry, Collaboration

PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus royalties on net sales.

Key Points: 
  • PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus royalties on net sales.
  • TOKYO, Nov. 28, 2023 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly").
  • Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM's proprietary PepMetics® technology.
  • "We are very excited to enter into this collaboration with Lilly as we apply our technology to expand the field of drug discovery into a novel approach to drug the PPI targets," said Dai Takehara, President and Chief Executive Officer of PRISM Biolab.

EQS-News: Cannovum Cannabis AG: High-profile business leaders from advertising and retail join the Supervisory Board for the legalization of cannabis

Retrieved on: 
onsdag, december 6, 2023
DTC, CBD, Luxora, Arkansas, Supervisory board, PPI, Bundestag, ISIN, Cannabis, Marketing, Advertising, Drug

Cannovum Cannabis AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) is ideally positioned for the upcoming legalization of cannabis.

Key Points: 
  • Cannovum Cannabis AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) is ideally positioned for the upcoming legalization of cannabis.
  • Two new Supervisory Board members support the company with their extensive expertise and many years of experience.
  • Cannovum Cannabis AG is pleased to announce the election of Fritz Hendrick Melle as Chairman of the Supervisory Board.
  • Their unique skills and experience will help guide Cannovum Cannabis AG on its path to further success," said Klaus Madzia, CEO of Cannovum Cannabis AG.

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Retrieved on: 
torsdag, november 9, 2023
FDA, Research, Food, PPI, Vonoprazan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Heartburn, Helicobacter pylori, Tablet, Clinical trial, Hercules, Commercial, New Drug Application, Enzyme inhibitor, NDA, Safety, Leyland Royal Tiger PSU, PARK, Chemistry, Patient, NERD, Gastroesophageal reflux disease, Esophagitis, State, Pharmaceutical industry, Video game, Bank, GERD

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Net loss for the third quarter ended September 30, 2023, was $43.2 million, compared to $51.1 million for third quarter 2022.
  • Third quarter 2023 net loss included a non-cash charge related to stock-based compensation of $6.1 million compared to $5.8 million for third quarter 2022.
  • Research and development expenses for the third quarter 2023 were $12.3 million, a decrease of $6.7 million compared to $19.0 million for third quarter 2022.
  • General and administrative expenses for the third quarter 2023 were $23.4 million, a decrease of $0.1 million compared to $23.5 million for third quarter 2022.